Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977072 | 0.86 | KMT2A (0.53) | KMT2AALDH1A1XDHCA12CA1 | |
| SCHEMBL4281000 | 0.85 | ALDH1A1 (0.49) | KMT2AALDH1A1XDHCYP1A2CYP2C19 | |
| SCHEMBL3545163 | 0.84 | KMT2A (0.58) | KMT2AALDH1A1XDHCA12CA1 | |
| SCHEMBL1980076 | 0.83 | NOTUM (0.56) | KMT2AALDH1A1XDHCA12CA1 | |
| SCHEMBL403444 | 0.83 | CA12 (0.54) | KMT2AALDH1A1XDHCA12CA1 | |
| SCHEMBL12619015 | 0.83 | RORC (0.45) | KMT2AALDH1A1CA12CA1CA2 | |
| SCHEMBL28031421 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2CA4 | |
| SCHEMBL16956910 | 0.82 | ALDH1A1 (0.44) | KMT2AALDH1A1XDHCYP1A2CYP2C19 | |
| SCHEMBL9005609 | 0.81 | TTR (0.56) | KMT2AALDH1A1XDHCA12CA1 | |
| SCHEMBL2543398 | 0.81 | KMT2A (0.55) | KMT2AALDH1A1XDHCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4116294-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-01-11 | — | — | EP | disclosed |
| EP-3492465-B1 | S1P1 AGONIST AND APPLICATION THEREOF | SHIJIAZHUANG SAGACITY NEW DRUG DEV CO LTD (CN) | 2021-03-24 | — | — | EP | disclosed |
| EP-3492465-A1 | S1P1 AGONIST AND APPLICATION THEREOF | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| EP-2794563-B1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-22 | — | — | EP | disclosed |
| CN-104011021-B | heterocyclic derivatives and their use as prostaglandin D2 receptor modulators | 埃科特莱茵药品有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9255090-B2 | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-09 | — | — | US | disclosed |
| US-20030144320-A1 | For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders | SMITHKLINE BEECHAM P.L.C. | 2003-07-31 | — | — | US | disclosed |
| EP-1102769-B1 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | SMITHKLINE BEECHAM P.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6410555-B1 | ANTIEPILEPTIC AGENTS; HEADACHES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-25 | — | — | US | disclosed |
| CN-1324359-A | Tricyclic carboxamides | SMITHKLINE BEECHAM PLC (GB) | 2001-11-28 | — | — | CN | disclosed |
| CN-1311789-A | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | SMITHKLINE BEECHAM PLC (GB) | 2001-09-05 | — | — | CN | disclosed |
| US-20010016657-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2001-08-23 | — | — | US | disclosed |
| US-6245778-B1 | 1,6-naphthyridine anti-convulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-06-12 | — | — | US | disclosed |
| EP-1102769-A2 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008020-A2 | TRICYCLIC CARBOXAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | CNR1, SCN1B, CNR2 | KMT2A 2431/4885ALDH1A1 2827/4885XDH 1833/4885 |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | AZI2, GABBR2, CNDP2 | KMT2A 919/4885ALDH1A1 284/4885XDH 303/4885 |
| US-20010016657-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | KMT2A 445/4885ALDH1A1 494/4885XDH 566/4885 |
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | AZI2, GABBR2, CNDP2 | KMT2A 919/4885ALDH1A1 284/4885XDH 303/4885 |
| US-20030144320-A1 | For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders | PNMT, SLC6A2, GABBR1 | KMT2A 1389/4885ALDH1A1 464/4885XDH 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.